


## Palazestrant

<b>Cat. No.:</b>	HY-148789		
<b>CAS No.:</b>	2092925-89-6		
<b>Molecular Formula:</b>	C <sub>28</sub> H <sub>36</sub> FN <sub>3</sub> O		
<b>Molecular Weight:</b>	449.6		
<b>Target:</b>	Estrogen Receptor/ERR		
<b>Pathway:</b>	Vitamin D Related/Nuclear Receptor		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 22.22 mg/mL (49.42 mM; ultrasonic and adjust pH to 3 with 1M HCl)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.2242 mL	11.1210 mL	22.2420 mL
	5 mM	0.4448 mL	2.2242 mL	4.4484 mL
	10 mM	0.2224 mL	1.1121 mL	2.2242 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Palazestrant is an antiestrogen and antineoplastic agent. Palazestrant in combination with a HER2 inhibitor, works on ER<sup>+</sup>/HER2<sup>+</sup> cancer<sup>[1][2]</sup>.

### REFERENCES

[1]. Harmon CL, et al. Methods of treating estrogen receptor-associated diseases such as ER<sup>+</sup>/HER2<sup>+</sup> cancer using an estrogen receptor antagonist: World Intellectual Property Organization, WO2023283329. 2023-01-12.

[2]. WHO Drug Information-World Health Organization (WHO).

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA